Ibandronate Sodium Tablets SPE2D2-25-R-0019
Summary
AI-generated · Aug 24, 2025Ibandronate Sodium Tablets, 150 mg in 3-count packs, will be procured under a national requirements contract to establish a national supply source for multiple federal customers through prime vendor programs. The contract will be firm-fixed-price, requirements-type, unrestricted and fully competitive, with a 1-year base period and four 1-year option years, and it will be solicited as a commercial item under FAR Part 12.
A subsequent Combined Synopsis/Solicitation has been issued (SPE2D2-25-R-0019), signaling the formal solicitation stage for the same item. This move from the presolicitation notice confirms the formal procurement is underway, with proposals open from all sources via the established posting platforms (DIBBS and SAM.gov).
The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Ibandronate Sodium Tablets. Procurement details follow. Ibandronate Sodium 150MG in 3 count packs. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency. A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov/. Interested parties should contact Christopher Newman (445-737-7371) (christopher.newman@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is July of 2025. DLA reserves the right to issue the solicitation before or after the projected solicitation date.
From Presolicitation posted on Jul 09, 2025SPE2D2-25-R-0019 Ibandronate Sodium Tablets
From Combined Synopsis/Solicitation posted on Aug 21, 2025SPE2D2-25-R-0019 Ibandronate Sodium Tablets
From Combined Synopsis/Solicitation posted on Sep 11, 2025SPE2D2-25-R-0019 Ibandronate Sodium Tablets
From Combined Synopsis/Solicitation posted on Sep 22, 2025SPE2D2-25-R-0019 Ibandronate Sodium Tablets
From Combined Synopsis/Solicitation posted on Oct 06, 2025Notice history
5-
Presolicitation Posted Jul 09, 2025
-
Combined Synopsis/Solicitation Posted Aug 21, 2025View changes (3)
- Description: Description was updated
- Notice Type: Presolicitation → Combined Synopsis/Solicitation
- Response Deadline: Not set → Sep 22, 2025
-
Combined Synopsis/Solicitation Posted Sep 11, 2025No changes from previous notice
-
Combined Synopsis/Solicitation Posted Sep 22, 2025View changes (1)
- Response Deadline: Sep 22, 2025 → Oct 06, 2025
-
Combined Synopsis/Solicitation LATEST Posted Oct 06, 2025View changes (1)
- Response Deadline: Oct 06, 2025 → Oct 10, 2025
Details
Award Information
Not yet awarded
Contacts
Phone
Phone